Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04236479 · ClinicalTrials.gov registry record · Phase 1
Mesenchymal Stromal Cells for Infants With Congenital Heart Disease (MedCaP)
A Phase 1 study of Congenital Heart Disease (CHD), sponsored by Catherine Bollard.
- Active
- Registry status
- Phase 1
- Development phase
- 17
- Enrollment target
- 1
- Study location
NCT04236479: Active Phase 1 study of Congenital Heart Disease (CHD), sponsored by Catherine Bollard.
NCT04236479 is a Phase 1 study of Congenital Heart Disease (CHD) that is active but no longer recruiting, run by Catherine Bollard. The registered enrollment target is 17 participants, below the 212-participant average among 3 other Congenital Heart Disease (CHD) trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04236479, a Phase 1 study of Congenital Heart Disease (CHD), is active but no longer recruiting, sponsored by Catherine Bollard.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 17 participants
- Enrollment target
- 1
- Study location
Study Summary
The proposed study will be a prospective, open-label, single-center, safety and feasibility phase 1 trial of allogeneic bone marrow-derived mesenchymal stromal cell (BM-MSC) delivery though cardiopulmonary bypass (CPB) using a homogeneous population of infants with congenital heart disease (CHD) who will be undergoing a two-ventricle repair within the first six months of life
Primary Outcome
Dose Limiting Toxicity is attributable to the MSC administration.
Conditions Studied
Interventions
- BIOLOGICAL BM-MSC
Study Locations (1)
District of Columbia
- Children's National Health System - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2020-07-29 |
| Est. Completion | 2026-09 |
| Phase | Phase 1 |
What the registry record for NCT04236479 still lists
NCT04236479 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 17 participants, a relatively small participant target, below the 212-participant average among 3 other Congenital Heart Disease (CHD) trials with a reported enrollment target (92% lower).
The record links to 1 condition, with Congenital Heart Disease (CHD) appearing as the primary indexed condition, and to 1 intervention - of which BM-MSC is the first listed.
NCT04236479 reports a single indexed study location in District of Columbia.
Frequently Asked Questions
What is clinical trial NCT04236479 about?
NCT04236479 is a clinical study titled "Mesenchymal Stromal Cells for Infants With Congenital Heart Disease (MedCaP)". The proposed study will be a prospective, open-label, single-center, safety and feasibility phase 1 trial of allogeneic bone marrow-derived mesenchymal stromal cell (BM-MSC) delivery though cardiopulmonary bypass (CPB) using a homogeneous population of infants with congenital heart disease (CHD) who...
What is the current status of trial NCT04236479?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 17 participants. The study started on 2020-07-29. Estimated completion is 2026-09.
What conditions does trial NCT04236479 study?
This clinical trial studies the following conditions: Congenital Heart Disease (CHD).
What interventions are being tested in trial NCT04236479?
The interventions under investigation include: BM-MSC (BIOLOGICAL).
Who is sponsoring clinical trial NCT04236479?
This trial is sponsored by Catherine Bollard, which has 14 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04236479 being conducted?
This trial has 1 study location across District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Congenital Heart Disease (CHD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02090140 · 17 participants · NA
Microfracture Versus Adipose Derived Stem Cells for the Treatment of Articular Cartilage Defects
- NCT03317860 · 17 participants · NA
Improving Measurement and Treatment of Post-stroke Neglect
- NCT04356469 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Non-Malignant Hematological Disorders in Children
- NCT04414046 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Primary Immunodeficiency and Inherited Metabolic Disorders in Children
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI